Kedrion Biopharma Expands Immunoglobulin Therapies Portfolio, Gains Commercial Rights in the U.S. to BIVIGAM®, a Recently Approved IGIV Brand
FORT LEE, N.J.--(BUSINESS WIRE)--Kedrion Biopharma Immunoglobulin portfolio has expanded to include four brands in the United States
